Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280843 | 0.93 | PDE5A (0.71) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7280050 | 0.83 | PDE5A (0.84) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7439183 | 0.83 | PDE5A (0.73) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7279816 | 0.83 | PDE5A (0.59) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7290371 | 0.83 | PDE5A (0.56) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7278130 | 0.82 | PDE5A (0.75) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7289858 | 0.82 | PDE5A (0.57) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7279350 | 0.82 | PDE5A (0.58) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| Hydrochloric Acid SCHEMBL7442487 | 0.82 | PDE5A (0.73) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL7280221 | 0.82 | PDE5A (0.70) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | PDE5A 3794/4885TBXAS1 977/4885PDE3B 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.